



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Adebrelimab

| | |
|-----------|---|
| Cat. No.: | HY-P99422 |
| CAS No.: | 2247114-85-6 |
| Target: | PD-1/PD-L1; Apoptosis |
| Pathway: | Immunology/Inflammation; Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | | | | | | | | | | | | | | | | | | | | | | |
|--------------------|---|------------|-------------------------|----------------|--|------------------|----------|---------|---|------------|-------------------------|----------------|--------------------|------------------|----------|---------|--------------------------|------------|-------------------------|----------------|--------------------|------------------|----------|
| Description | Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) ^{[1][2]} . | | | | | | | | | | | | | | | | | | | | | | |
| In Vitro | <p>Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) inhibits effects on the cell proliferation, migration, invasion of SK-BR-3 and AU565 cells^[1].</p> <p>Adebrelimab (SHR-1316; 0.1-1mg/mL; 48 hours) downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulates the expression FOXO1^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SK-BR-3 and AU565 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>The viability of SK-BR-3 and AU565 cells decreased gradually.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SK-BR-3 and AU565 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1 mg/mL, 1 mg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Promoted cell apoptosis.</td> </tr> </table> <p>Cell Migration Assay ^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SK-BR-3 and AU565 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1 mg/mL, 1 mg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> </table> | Cell Line: | SK-BR-3 and AU565 cells | Concentration: | 0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL | Incubation Time: | 48 hours | Result: | The viability of SK-BR-3 and AU565 cells decreased gradually. | Cell Line: | SK-BR-3 and AU565 cells | Concentration: | 0.1 mg/mL, 1 mg/mL | Incubation Time: | 48 hours | Result: | Promoted cell apoptosis. | Cell Line: | SK-BR-3 and AU565 cells | Concentration: | 0.1 mg/mL, 1 mg/mL | Incubation Time: | 48 hours |
| Cell Line: | SK-BR-3 and AU565 cells | | | | | | | | | | | | | | | | | | | | | | |
| Concentration: | 0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL | | | | | | | | | | | | | | | | | | | | | | |
| Incubation Time: | 48 hours | | | | | | | | | | | | | | | | | | | | | | |
| Result: | The viability of SK-BR-3 and AU565 cells decreased gradually. | | | | | | | | | | | | | | | | | | | | | | |
| Cell Line: | SK-BR-3 and AU565 cells | | | | | | | | | | | | | | | | | | | | | | |
| Concentration: | 0.1 mg/mL, 1 mg/mL | | | | | | | | | | | | | | | | | | | | | | |
| Incubation Time: | 48 hours | | | | | | | | | | | | | | | | | | | | | | |
| Result: | Promoted cell apoptosis. | | | | | | | | | | | | | | | | | | | | | | |
| Cell Line: | SK-BR-3 and AU565 cells | | | | | | | | | | | | | | | | | | | | | | |
| Concentration: | 0.1 mg/mL, 1 mg/mL | | | | | | | | | | | | | | | | | | | | | | |
| Incubation Time: | 48 hours | | | | | | | | | | | | | | | | | | | | | | |

| | | |
|----------------|--|--|
| | Result: | Decreased the migration rate of SK-BR -3 and AU565 cells. |
| | Western Blot Analysis ^[1] | |
| | Cell Line: | SK-BR-3 and AU565 cells |
| | Concentration: | 0.1 mg/mL, 1 mg/mL |
| | Incubation Time: | 48 hours |
| | Result: | Downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1. |
| In Vivo | Adebrelimab (SHR-1316; 200 µg; three times a week; for 21 days) shows inhibition effects on tumor growth ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells [1] |
| | Dosage: | 200 µg |
| | Administration: | Three times a week; for 21 days |
| | Result: | Significantly inhibited tumor growth. |

REFERENCES

[1]. Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positive breast cancer. Research Square. May 19th, 2022.

[2]. Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA